As interest in CAR T cells and immune-based oncology therapies increases, efficient phenotyping of cell therapy products ...

TD2 Oncology delivers fully integrated preclinical, regulatory, and clinical services for cancer drug development. In response to advances in In Vivo CAR-T engineering, TD2 Oncology launches flow ...

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

CAR-T translational research demands precise, reproducible, and scalable flow cytometry workflows. Manual centrifugation and antibody preparation steps remain major sources of variability and cell ...

The discovery of novel immunotherapies that specifically target and enhance the T-cell response against cancer, for example CAR-T cells, bispecific antibodies and checkpoint inhibitors, is a rapidly ...

A low-profile child of the '60s, flow cytometry didn't capture the imagination of most researchers until the early 1980s. The decade saw the birth of the AIDS epidemic, and as attention focused on HIV ...

Rapid developments in gene-modified cell therapies, especially CAR T-cell therapies, has increased demand for fast and reliable analytics methods for research, in-process development, and ...

Northwestern Medicine scientists have identified the cellular mechanisms that cause immune cells to differentiate and ultimately lose function during viral infection, findings that could improve ...

Creating a clear and well-defined bioanalytical methodology to quantify humoral and cellular immune responses is critical for ...